Barclays Maintains Overweight on Sutro Biopharma, Raises Price Target to $57
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
Sutro Biopharma Q3 EPS $(1.90) Beats $(1.91) Estimate, Sales $9.100M Miss $10.342M Estimate
Here's Why Sutro Biopharma (STRO) is Poised for a Turnaround After Losing 34.2% in 4 Weeks
Sutro Biopharma to Participate in Upcoming Investor Conferences
Down 39.8% in 4 Weeks, Here's Why Sutro Biopharma (STRO) Looks Ripe for a Turnaround
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
Sutro Biopharma Doses First Patient In Its Phase 1 Trial Of STRO-006 In Patients With Range Of Solid Tumors; Initial Clinical Data Expected In H2 2027
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34
STRO Stock Plummets 15% — What Drove The Selloff?
Why is Sutro Biopharma Stock Falling On Wednesday?
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
Sutro Biopharma Q2 EPS $(2.33) Misses $(2.19) Estimate, Sales $9.839M Miss $13.048M Estimate
Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50
News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts
Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.